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How Medicare Could Get
Better Prices On Prescription
Drugs
Increased formulary flexibility and value-based pricing are among the
options that should be considered in the context of health reform.
by Kevin Outterson and Aaron S. Kesselheim
ABSTRACT: Congress may reform drug pricing policies under Medicare Part D as part of a
larger health reform effort. Currently, the “noninterference” provision prevents the govern-
ment from negotiating drug prices on behalf of Medicare Part D prescription drug plans.
Commonly considered reform proposals borrow ideas from Medicaid, either through return-
ing dual eligibles to Medicaid drug pricing or by imposing mandatory rebates across the
Part D population. We examine a menu of other options, including value-based pricing; ex-
pansion of generic and therapeutically equivalent substitution; increased formulary diver-
sity; importation; and limited antitrust waivers. These latter options may reduce federal
spending without direct government price negotiations. [Health Aff (Millwood) 2009;28(5):
w832–41 (published online 30 July 2009;10.1377/hlthaff.28.5.w832)]
A
n $ 8 0 b i l l i o n i n f o r m a l ag r e e m e n t by the drug industry to support
Medicare and Medicaid drug benefits has raised the profile of the costly
Medicare Part D prescription drug program as Congress crafts broad
health care reform legislation. The 111th Congress may address several aspects of
Part D for legislative reform, including the “noninterference” provision in the
Medicare Prescription Drug, Improvement, and Modernization Act (MMA) of
2006, which says that the secretary of Health and Human Services (HHS) cannot
“interfere with the negotiations” or “institute a price structure” for Part D drugs.
Prohibiting such negotiations has been criticized as artificially raising Part D drug
prices and increasing the costs of the program.1 With the noninterference provi-
sion in place, price negotiations occur at the level of the individual Part D insur-
ance plans, using private-sector purchasing strategies.
In this paper we evaluate several options to reduce federal spending on Part D
drugs (Exhibit 1), focusing on the most feasible ideas. We first examine federal ne-
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gotiations and other direct interventions in the Part D market; we then turn to ap-
proaches that avoid direct government price negotiations.
Direct Federal Negotiations
In the years since Part D was enacted, a number of reform proposals have sought
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EXHIBIT 1
Medicare Part D Drug Price Reform Options
Category/proposala Strengths Weaknesses
Direct federal interventions
Price controls Large static savings Administratively complex; political process
vulnerable to lobbying; formidable political
opposition
International reference pricing Large static savings; administratively
straightforward
Savings tend to dissipate over time as
companies react; policy levers ceded to
referenced reimbursement systems
Profit controls Existing model in U.K. Largely ineffective due to company
reactions to profit-based measures
(transfer pricing)
Federal negotiations Direct federal role without a
complicated administrative process
Horizontal inequity; unknown effectiveness;
rent seeking
Binding arbitration Evidence-based legal process Companies have opposed similar
processes in NICE and PBS
Public option plans Limited scope, leaving the remainder
of the market untouched
Political opposition; unknown effectiveness
Medicaid-based
Mandatory rebates Huge static savings with well-tested
administrative model
Arbitrary rebate levels; company responses
will erode savings over time
Return dual eligibles to Medicaid
pricing
Significant static savings; known
implementation model
One-time clinical cost of switching back
Other proposals
Formulary design Permits Part D plans to use
commercial formulary designs;
significant savings
Savings will take time; formulary
restrictions have clinical effects; patients
must make educated choices; opposition
by patient advocacy groups
Generic and therapeutic substitution Extends a proven savings model Expansion to therapeutic classes and
biosimilars may have clinical effects
Antitrust waivers Low risk Unproven
Importation Some static savings Secondary effects in foreign markets;
potential safety questions; savings unlikely
to persist; cedes policy levers to foreign
reimbursement systems
Value-based pricing Transformative information spillovers
to U.S. health care market; significant
existing international evidence base
and U.S. commitment to fund
additional studies
Some have tried to create tension between
comparative effectiveness and cost-
effectiveness; history of political opposition
to NICE and PBS determinations; lag time
for new studies
SOURCE: Authors’ analysis.
NOTES: NICE is (U.K.) National Institute for Health and Clinical Effectiveness. PBS is (Australian) Pharmacy Benefits Scheme.
a All proposals share the potential for dynamic changes to research and development.
to overturn the noninterference provision. The most straightforward plan would
simply remove the offending section from MMA. But the structure of Part D, re-
plete with many private plans, poses difficult administrative and practical hurdles
to successful federal price negotiation.2 The Congressional Budget Office (CBO)
concluded that HHS would have insufficient leverage to negotiate on behalf of
plans, given that discounts are driven more by moving market share in competitive
drug classes than by gross volume.3
In addition, the largest Part D contractors compete across many health insur-
ance markets, and it is unclear how federally negotiated prices under Part D could
be limited to Medicare. Negotiators would need to account for favorable price dis-
crimination in other U.S. programs and protect low-cost federal acquisition pro-
grams such as the Section 340b public health program and the Federal Supply
Schedule (FSS).4 A recent analysis projected $21.9 billion in annual savings if Part
D adopted FSS pricing.5 However, if Part D and FSS prices are linked, the FSS may
no longer be able to achieve the same discounts. This dynamic effect might greatly
reduce the net savings to the federal government.
 Negotiations for a public drug plan. Another direct federal approach pro-
posed in recent legislative sessions6 would require negotiations, but only for a pub-
licly owned drug plan.7 Leading congressional Democrats support a “public plan op-
tion” for health reform generally; the public plan would negotiate prices, but only for
itself. Successful negotiations would require a credible threat of formulary exclu-
sion, which is difficult in a national public plan with a safety-net role.
 Other direct interventions. Other direct federal interventions have also been
discussed—including international reference pricing, price controls, profit limita-
tions,8 and binding arbitration for sole-source Part D drugs.9 All of these proposals
face strong political opposition in the United States, with the possible exception of
the arbitration proposal.
Medicaid-Based Pricing: Dual Eligibles And Rebates
A second category of reforms borrows ideas from the Medicaid program.
Medicaid receives substantial discounts on drugs, in both mandatory federal re-
bates and state-negotiated supplemental rebates. A House committee has esti-
mated that Part D pays about 30 percent higher drug prices than Medicaid pays.10
Congress moved Medicaid patients who were also eligible for Part D (so-called
dual eligibles) into Medicare Part D, meaning that such patients lost access to
Medicaid rebates. Although patients’ experiences have been mixed, studies have
revealed that certain high-risk patients had problems maintaining access after the
switch.11, 12 State budgets did not benefit, as state Medicaid savings were recovered
by a federal charge called the “clawback,” which led to unsuccessful litigation by
some states against the federal government before the Supreme Court.13
 Mandatory rebates. Two Medicaid-based pricing proposals have recently
been discussed. The greatest direct cost savings would come from applying the
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Medicaid mandatory rebate scheme to Part D. The CBO estimated that a 15 percent
mandatory rebate would reduce federal expenses by $33 billion in 2010–2014 and
$110 billion in 2010–2019.2 Mandatory rebates are economically similar to a federal
tax on the patent-based drug industry, with the proceeds supporting Part D. This
model has the benefit of simplicity, and it may be reasonable to require participating
companies to directly support a system that has been so profitable for them. How-
ever, mandatory rebates would be prone to gaming by companies and politically ex-
pedient adjustments by Congress, which could revisit the relatively arbitrary rebate
level in the future. All of the options would also reduce drug company profits.14
 Return dual eligibles to Medicaid pricing. The second, perhaps more feasi-
ble, step would return the 6.2 million dual eligibles to Medicaid pricing, which
could lead to substantial savings15—perhaps as much as $2.8 billion annually.16 As
Richard Frank and Joseph Newhouse have suggested, this step involves less risk,
since major problems were not apparent under the prior regime.9
Reforms To Promote More-Effective Private Negotiations
Other possible reforms seek to improve private negotiations by Part D plans.
We evaluate a menu of five options that could effectively give more negotiating
power to Part D plans. These proposals retain the current framework of a compet-
itive prescription drug marketplace, with less-intrusive government intervention.
 Formulary design flexibility. Formulary design is a widely used private-
sector tool for controlling health plans’ drug costs. Medicare limited the freedom of
Part D plans to control their formularies through rules such as the safe harbor guide-
lines established by the U.S. Pharmacopeia17 and MMA’s requirement that Part D
plans cover at least two drugs per class.18
The CMS went beyond the statute, requiring at least one drug in each subclass
as well. In addition, the CMS has given special protections to six classes of drugs,
requiring that “all or substantially all drugs” in the classes be included in the for-
mularies.18 This rule effectively eliminates Part D drug price negotiations over
anticonvulsants, antidepressants, antineoplastics, antipsychotics, antiretrovirals,
and immunosuppressants. In other classes, Part D plans routinely exclude some
drugs as part of the normal commercial formulary process.19 The 110th Congress
solidified and expanded the protected classes. The July 2008 physician payment
update legislation gave the CMS clear statutory authority to expand the protected
drug classes and created a cumbersome process that delays competition within
the classes.20
These rules limit the negotiating power of Part D plans and make drugs in those
classes more expensive. A Milliman study found that these six protected classes
accounted for 16.8–33.2 percent of Part D drug costs by Part D plan administra-
tors. Reversing this one rule would decrease prices in these classes by 9–11 per-
cent, for a projected Part D savings of $511 million per year.21 To ease the negative
effect such restrictions can have on price negotiations, Congress could modify the
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Medicare Part D rules to give private drug plans more freedom to control their for-
mularies. More-flexible formularies would permit more-aggressive negotiations
by Part D plans, because the plans would have more maneuvering room to negoti-
ate for deeper discounts, as they do with some of their non-Medicare plans.22
Because permitting tighter formularies for Part D plans could have real clinical
and financial effects, modifications would have to be monitored closely. For exam-
ple, tighter formularies might be adopted by Medicare Advantage Prescription
Drug (MA-PD) plans as a device to discourage enrollment by beneficiaries with
certain chronic conditions. In the absence of effective risk adjustments in Medi-
care contracts, experimentation with tighter formulary designs might be limited
to stand-alone plans. In addition, formulary stability is important; rules should
continue to prohibit changes that negatively affect a Part D formulary or drug tier
structure within a plan year.23 Patients will need to be aware of the changes in
their plan well in advance of the annual enrollment period, but Medicare patients
do not have a good track record in efficiently selecting Part D plans.24 Plans could
be required to give beneficiaries advance notice of any prospective formulary or
tier design change affecting any drug purchased in the prior three years.
Current Medicare rules allow some midyear benefit alterations that could di-
rectly affect patient care, in the form of drug price changes at the point of pur-
chase. These changes can occur without notice, even after a beneficiary has com-
mitted to a particular plan. Physicians and policymakers should be concerned
about the potential risks this current arrangement may pose for patients. This
proposal is not a national formulary; it simply permits more heterogeneity among
private formularies.
 Extended generic and therapeutic substitution. Substitution of generic
drugs for their brand-name equivalents is well established as a way of reducing what
consumers and health plans pay for prescription drugs without affecting clinical
outcomes.25 It is important to note that generic substitution strategies to date have
been effective, and their history of success may limit future potential savings.26
State generic substitution laws vary widely in their effectiveness, and consum-
ers’ willingness to switch voluntarily is less than optimal.27 In some states, laws
have been proposed to reduce the scope of generic substitution for certain classes
of drugs. A federal generic substitution law is a possible response: it would pre-
empt local legislative retrenchments and promote uniform generic access.
Some will argue that these changes are not needed, since Medicare Part D plans
already have substantial and growing generic use rates (Exhibit 2), but expanded
generic substitution would accelerate this trend. Medicare Part D plans vary
greatly in generic use rates, ranging in 2008 from a high of 89.5 percent to a low of
49.1 percent.28 These variations may represent consumers’ preferences among the
various plan designs, as patients who are unwilling or unable to accept particular
generics choose higher-price plans. But given the clinical equivalence of nearly all
brand-name and generic drugs,29 there may still be room for improving generic
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substitution rates.
Another way to achieve price savings would be to expand generic substitution
laws to include different drugs within carefully selected therapeutic classes, in-
cluding between similar biologic molecules. Congress is considering a form of
therapeutic substitution legislation to permit “generic” biological molecules,
known as “biosimilars” or “follow-on biologics.” Current law for generic entry of
small-molecule chemicals is inadequate for more complex large-molecule biologi-
cal products. The CBO estimates savings at $9.2–$12 billion over ten years if the
federal law is changed to permit follow-on biologics.2 However, it is important to
remember the role of state generic substitution laws, as well, to aid in the uptake
of follow-on biologics.
Therapeutic substitution can also occur with traditional, nonbiological drugs.
The clinical implications of therapeutic substitution must be addressed, because
not all drugs within a class are substitutable for all patients. In December 2008 the
CBO described a proposed Medicaid therapeutic substitution program in two
classes: proton-pump inhibitors and non-benzodiazepine hypnotic agents for
treating insomnia.2 Although the initial savings are projected to be quite small,
this important trial of therapeutic substitution could be implemented and care-
fully evaluated for future expansions.
Generic utilization can also be supported by reference-based copayment struc-
tures. This copayment is the difference between the generic and brand-name price
when a generic is available. In January 2009 the CMS proposed a ban on reference-
based copays30 and other variable copayments, to take effect in 2010. The rule was
finalized in the 2010 Call Letter issued 30 March 2009.31 Consumer groups such as
AARP complained about reference-based copays in Part D plans, even though they
apply only when a generic is available but not chosen by the patient. In this cir-
cumstance, the additional financial burden is probably justified, especially if the
patient is clearly informed of the lower-cost generic option at the pharmacy.
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EXHIBIT 2
Quarterly Use Of Generic Drugs In Medicare Part D, As Percentage Of Paid Part D
Claims, 2006–2008
SOURCE: Centers for Medicare and Medicaid Services, Medicare Part D Generic Drug Utilization Rates (2006–2008),











 Limited antitrust waivers. Antitrust laws prohibit joint negotiations by
Medicare drug plans—such plans must all negotiate individually or through phar-
macy benefit managers (PBMs). Such arrangements limit the market power of Part
D plans. To address this problem, Congress could give private plans limited waivers
from state and federal antitrust laws, allowing them to voluntarily band together in
negotiating groups to seek lower drug prices. The waiver groups could be limited to
no more than one-quarter of the Part D market, allowing a reasonable size to negoti-
ate better discounts, without creating a monopsony, where a single buyer would
have disproportionate leverage.
Although this option is straightforward in theory, it is hard to know in advance
whether companies would use it. The larger companies might prefer to continue
to negotiate independently. But smaller plans lacking market power might find
this option attractive, especially if the joint negotiations were facilitated through
their PBMs. Frank and Newhouse suggest that the market for Medicare prescrip-
tion drug plans (PDPs) might be too fragmented, leaving some plans with “weaker
than anticipated” negotiating power.9 If so, limited antitrust waivers might be able
to recalibrate the market.
 Importation. For several years, Congress has considered various proposals to
import lower-price drugs from countries with well-regulated pharmaceutical mar-
kets, such as Canada, Australia, and western Europe. Such a system was most re-
cently proposed in 2009, permitting imports by individual patients and drug whole-
salers from an FDA-approved set of sources.32 Additional legislation might not even
be necessary, as HHS could use existing statutory authority to certify the safety of
imports.33 Alternatively, Part D plans could agree to waive the right to import certain
drugs in exchange for price discounts from the manufacturer. This waiver option re-
duces prices without invoking potential problems with importation.34
However, importation plans raise important questions, such as sustainability
and the long-term dynamic effects on global prices and research and development
(R&D).35 Arbitrage or parallel trade involves moving identical products from low-
price to higher-price markets, earning a profit on the difference. Over time, com-
panies react to parallel trade to limit its scope and profitability. Also, although
questions are often raised about safety, a fully regulated importation process will
be much safer than the unregulated Internet and personal channels that some pa-
tients use now.
 Value-based pricing. As a direct result of the quality movement in health care,
Medicare is exploring important changes in how to pay for health services, includ-
ing comparative effectiveness and value-based pricing incentives.36
Comparative effectiveness studies may include head-to-head trials of compet-
ing drugs, expanding the scope of evidence-based medicine. The American Recov-
ery and Reinvestment Act of 2009 (the so-called stimulus bill) provided $1.1 bil-
lion to fund research comparing the effectiveness of health care treatments. It also
established the Federal Coordinating Council for Comparative Effectiveness Re-
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search, which will conduct this research along with HHS, the National Institutes
of Health (NIH), and the Agency for Healthcare Research and Quality (AHRQ).
Value-based pricing for drugs adds the element of pharmacoeconomic analysis
to comparative effectiveness data. It may require greater reimbursement for out-
standing drugs with clear benefits over existing therapies, and less for drugs with
limited usefulness or complicated side-effect profiles.37 Although value-based
pricing does not necessarily lower the price of prescription drugs, its goal is to
identify and encourage the use of more cost-effective medicines. A limited domes-
tic test of value-based reimbursement in Part D could be an important step for-
ward, as recently proposed by the Medicare Payment Advisory Commission
(MedPAC).38
These U.S. efforts do not proceed in a vacuum. For the past decade, the National
Institute for Health and Clinical Excellence (NICE) in England has performed
comparative pharmacoeconomic and clinical analyses of drugs.39, 40 Other pro-
grams include the Australian Pharmaceutical Benefits Scheme41 and Oregon’s
Drug Effectiveness Review Project.42 A sizable international evidence base already
exists, and the United States should examine the lessons learned in England and
Australia.43 These results could inform the organization of the Part D plans in their
formularies, payment tiers, and step-therapy options, with spillover benefits well
beyond Medicare. A value-based reimbursement system could create and apply
information in transformative applications for public and private health care mar-
kets.44
Concluding Remarks
If Congress reforms Part D, it may be tempted to pursue interventions such as
direct repeal of the noninterference provision or mandatory rebates. Restoring
dual-eligible pricing is the better Medicaid-based strategy, especially if it can be
done without harming patients, the states, and providers. One option would be to
adopt dual-eligible pricing without actually moving dual eligibles’ prescription
drug financing back to Medicaid. In addition, more market-based reforms include
greater formulary flexibility, expanded generic and therapeutic substitution, anti-
trust waivers, drug importation, and value-based reimbursement. Each of these
reforms also suffers from various weaknesses, but they may be worth considering
as positive steps toward achieving lower prices for prescription drugs within
Medicare Part D and encouraging enrollees and their physicians to use effective,
yet less expensive, medicines.
The authors report no conflict-of-interest disclosures.
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